Literature DB >> 25459592

Coronary artery calcium and incident cerebrovascular events in an asymptomatic cohort. The MESA Study.

Ashleigh O Gibson1, Michael J Blaha2, Martinson K Arnan3, Ralph L Sacco4, Moyses Szklo5, David M Herrington1, Joseph Yeboah6.   

Abstract

OBJECTIVES: This study assessed the predictive value of coronary artery calcium (CAC) score for cerebrovascular events (CVE) in an asymptomatic multiethnic cohort.
BACKGROUND: The CAC score, a measure of atherosclerotic burden, has been shown to improve prediction of coronary heart disease events. However, the predictive value of CAC for CVE is unclear.
METHODS: CAC was measured at baseline examination of participants (N = 6,779) of MESA (Multi-Ethnic Study of Atherosclerosis) and then followed for an average of 9.5 ± 2.4 years for the diagnosis of incident CVE, defined as all strokes or transient ischemic attacks.
RESULTS: During the follow-up, 234 (3.5%) adjudicated CVE occurred. In Kaplan-Meier analysis, the presence of CAC was associated with a lower CVE event-free survival versus the absence of CAC (log-rank chi-square: 59.8, p < 0.0001). Log-transformed CAC was associated with increased risk for CVE after adjusting for age, sex, race/ethnicity, body mass index, systolic and diastolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, cigarette smoking status, blood pressure medication use, statin use, and interim atrial fibrillation (hazard ratio [HR]: 1.13 [95% confidence interval (CI): 1.07 to 1.20], p < 0.0001). The American College of Cardiology/American Heart Association-recommended CAC cutoff was also an independent predictor of CVE and strokes (HR: 1.70 [95% CI: 1.24 to 2.35], p = 0.001, and HR: 1.59 [95% CI: 1.11 to 2.27], p = 0.01, respectively). CAC was an independent predictor of CVE when analysis was stratified by sex or race/ethnicity and improved discrimination for CVE when added to the full model (c-statistic: 0.744 vs. 0.755). CAC also improved the discriminative ability of the Framingham stroke risk score for CVE.
CONCLUSIONS: CAC is an independent predictor of CVE and improves the discrimination afforded by current stroke risk factors or the Framingham stroke risk score for incident CVE in an initially asymptomatic multiethnic adult cohort.
Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cerebrovascular disease; coronary artery calcium score; prevention; risk prediction

Mesh:

Year:  2014        PMID: 25459592      PMCID: PMC4254694          DOI: 10.1016/j.jcmg.2014.07.009

Source DB:  PubMed          Journal:  JACC Cardiovasc Imaging        ISSN: 1876-7591


  34 in total

1.  Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program.

Authors:  Paul K Whelton; Jiang He; Lawrence J Appel; Jeffrey A Cutler; Stephen Havas; Theodore A Kotchen; Edward J Roccella; Ron Stout; Carlos Vallbona; Mary C Winston; Joanne Karimbakas
Journal:  JAMA       Date:  2002-10-16       Impact factor: 56.272

2.  2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  David C Goff; Donald M Lloyd-Jones; Glen Bennett; Sean Coady; Ralph B D'Agostino; Raymond Gibbons; Philip Greenland; Daniel T Lackland; Daniel Levy; Christopher J O'Donnell; Jennifer G Robinson; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Paul Sorlie; Neil J Stone; Peter W F Wilson; Harmon S Jordan; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli
Journal:  Circulation       Date:  2013-11-12       Impact factor: 29.690

3.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.

Authors:  Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2003-04-05       Impact factor: 79.321

4.  Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Eyal Shahar; Lloyd E Chambless; Wayne D Rosamond; Lori L Boland; Christie M Ballantyne; Paul G McGovern; A Richey Sharrett
Journal:  Stroke       Date:  2003-02-20       Impact factor: 7.914

5.  Total and HDL cholesterol and risk of stroke. EUROSTROKE: a collaborative study among research centres in Europe.

Authors:  M L Bots; P C Elwood; Y Nikitin; J T Salonen; A Freire de Concalves; D Inzitari; J Sivenius; V Benetou; J Tuomilehto; P J Koudstaal; D E Grobbee
Journal:  J Epidemiol Community Health       Date:  2002-02       Impact factor: 3.710

6.  Cholesterol predicts stroke mortality in the Women's Pooling Project.

Authors:  Richard B Horenstein; Dean E Smith; Lori Mosca
Journal:  Stroke       Date:  2002-07       Impact factor: 7.914

7.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

8.  Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis.

Authors:  Bruce M Psaty; Thomas Lumley; Curt D Furberg; Gina Schellenbaum; Marco Pahor; Michael H Alderman; Noel S Weiss
Journal:  JAMA       Date:  2003-05-21       Impact factor: 56.272

9.  Multi-Ethnic Study of Atherosclerosis: objectives and design.

Authors:  Diane E Bild; David A Bluemke; Gregory L Burke; Robert Detrano; Ana V Diez Roux; Aaron R Folsom; Philip Greenland; David R Jacob; Richard Kronmal; Kiang Liu; Jennifer Clark Nelson; Daniel O'Leary; Mohammed F Saad; Steven Shea; Moyses Szklo; Russell P Tracy
Journal:  Am J Epidemiol       Date:  2002-11-01       Impact factor: 4.897

10.  Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials.

Authors:  Fiona Turnbull
Journal:  Lancet       Date:  2003-11-08       Impact factor: 79.321

View more
  36 in total

1.  Incident Cardiovascular Disease Among Adults With Blood Pressure <140/90 mm Hg.

Authors:  Gabriel S Tajeu; John N Booth; Lisandro D Colantonio; Rebecca F Gottesman; George Howard; Daniel T Lackland; Emily C O'Brien; Suzanne Oparil; Joseph Ravenell; Monika M Safford; Samantha R Seals; Daichi Shimbo; Steven Shea; Tanya M Spruill; Rikki M Tanner; Paul Muntner
Journal:  Circulation       Date:  2017-06-20       Impact factor: 29.690

2.  Ischemic stroke/transient ischemic attack events and carotid artery disease in the absence of or with minimal coronary artery calcification: Results from the Multi-Ethnic Study of Atherosclerosis.

Authors:  Kazuhiro Osawa; Rine Nakanishi; Robyn L McClelland; Joseph F Polak; Warrick Bishop; Ralph L Sacco; Indre Ceponiene; Negin Nezarat; Sina Rahmani; Hong Qi; Mitsuru Kanisawa; Matthew J Budoff
Journal:  Atherosclerosis       Date:  2018-05-17       Impact factor: 5.162

3.  The next generation of prognostic series: Where we can improve on risk stratification?

Authors:  Leslee J Shaw
Journal:  J Nucl Cardiol       Date:  2015-03-27       Impact factor: 5.952

Review 4.  Coronary Artery Calcification.

Authors:  Kazuhiro Osawa; Rine Nakanishi; Matthew Budoff
Journal:  Glob Heart       Date:  2016-09

5.  Guideline-based statin/lipid-lowering therapy eligibility for primary prevention and accuracy of coronary artery calcium and clinical cardiovascular events: The Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Peter Flueckiger; Waqas Qureshi; Erin D Michos; Michael Blaha; Gregory Burke; Veit Sandfort; David Herrington; Joseph Yeboah
Journal:  Clin Cardiol       Date:  2016-11-12       Impact factor: 2.882

6.  Incidental Coronary Artery Calcification and Stroke Risk in Patients With Atrial Fibrillation.

Authors:  Dustin Hillerson; Thomas Wool; Gbolahan O Ogunbayo; Vincent L Sorrell; Steve W Leung
Journal:  AJR Am J Roentgenol       Date:  2020-04-29       Impact factor: 3.959

7.  Rationale and design of the coronary artery calcium consortium: A multicenter cohort study.

Authors:  Michael J Blaha; Seamus P Whelton; Mahmoud Al Rifai; Zeina A Dardari; Leslee J Shaw; Mouaz H Al-Mallah; Kuni Matsushita; John A Rumberger; Daniel S Berman; Matthew J Budoff; Michael D Miedema; Khurram Nasir
Journal:  J Cardiovasc Comput Tomogr       Date:  2016-11-11

Review 8.  An Update on the Utility of Coronary Artery Calcium Scoring for Coronary Heart Disease and Cardiovascular Disease Risk Prediction.

Authors:  Sina Kianoush; Mahmoud Al Rifai; Miguel Cainzos-Achirica; Priya Umapathi; Garth Graham; Roger S Blumenthal; Khurram Nasir; Michael J Blaha
Journal:  Curr Atheroscler Rep       Date:  2016-03       Impact factor: 5.113

9.  2016 European Guidelines on cardiovascular disease prevention in clinical practice : The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts).

Authors:  Massimo F Piepoli
Journal:  Int J Behav Med       Date:  2017-06

10.  Coronary Artery Calcium and Risk of Dementia in MESA (Multi-Ethnic Study of Atherosclerosis).

Authors:  Akira Fujiyoshi; David R Jacobs; Annette L Fitzpatrick; Alvaro Alonso; Daniel A Duprez; A Richey Sharrett; Teresa Seeman; Michael J Blaha; José A Luchsinger; Stephen R Rapp
Journal:  Circ Cardiovasc Imaging       Date:  2017-05       Impact factor: 7.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.